EMCURE — Emcure Pharmaceuticals Share Price
0.000.00%
Last trade - 00:00- IN₹252.77bn
- IN₹262.01bn
- IN₹78.96bn
- 91
- 13
- 94
- 76
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 22.94 | ||
| PEG Ratio (f) | 1.06 | ||
| EPS Growth (f) | 27.69% | ||
| Dividend Yield (f) | 0.42% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 4.95 | ||
| Price to Tang. Book | 6.54 | ||
| Price to Free Cashflow | 36.27 | ||
| Price to Sales | 2.7 | ||
| EV to EBITDA | 15.42 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 19.13% | ||
| Return on Equity | 17.69% | ||
| Operating Margin | 13.41% | ||
Financial Summary
| Year End 31st Mar | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | IN₹m | 50,485.54 | 60,564.15 | 58,553.87 | 59,858.11 | 66,582.51 | 78,466 | 87,090.33 | 7.14% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -6.35 | +135.67 | +47.78 | -18.96 | -6.84 | +38.9 | +27.69 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Emcure Pharmaceuticals Limited is an India-based pharmaceutical company, which is engaged in developing, manufacturing and globally marketing a range of pharmaceutical products across several major therapeutic areas. It offers a range of products and services under formulations, biologics and APIs. It operates across a wide scope of areas, including gynecological, cardiology, antivirals, vitamins, pain/analgesics, anti-neoplastic, diabetes, anti-infective, respiratory, CNS and nephrology. Its brands include OROFER (Gynecological), BEVON (Vitamins), ZOSTUM (Anti- infectives), Ferium (Gynecological), EXHEP (Cardiovascular), Maxtra (Respiratory) and Pause (Blood-Related). Its API products include S-Amlodipine, Dydrogesterone, Ferric Carboxymaltose, Ferrous Ascorbate and Eribulin. Its biologics business offers various products, including Elaxim (cardiology), Vintor (nephrology), Xgrast (anti-neoplastic) and Pegex (anti- neoplastic). It has developed two platforms: Mammalian and Microbial.
Directors
- Last Annual
- March 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- April 16th, 1981
- Public Since
- July 10th, 2024
- No. of Shareholders
- 49
- No. of Employees
- 11,146
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- National Stock Exchange of India
- Shares in Issue
- 189,483,347
- Address
- Plot P-II, PUNE, 411057
- Web
- https://www.emcure.com/
- Phone
- +91 2035070033
- Contact
- Chetan Sharma
- Auditors
- BSR & Co. LLP
Upcoming Events for EMCURE
Q4 2025 Emcure Pharmaceuticals Ltd Earnings Call
Similar to EMCURE
Aarey Drugs and Pharmaceuticals
National Stock Exchange of India
Aarti Drugs
National Stock Exchange of India
Aarti Pharmalabs
National Stock Exchange of India
Abbott India
National Stock Exchange of India
Accent Microcell
National Stock Exchange of India
FAQ
What is the Emcure Pharmaceuticals share price?
As of Today at 20:25 UTC, shares in Emcure Pharmaceuticals are trading at IN₹1,076.00. This share price information is delayed by 15 minutes.
How has the Emcure Pharmaceuticals share price performed this year?
Shares in Emcure Pharmaceuticals last closed at IN₹1,076.00 and the price had moved by over the past 365 days. In terms of relative price strength the Emcure Pharmaceuticals share price has matched the S&P BSE 100 Index by over the past year.
What are the analyst and broker recommendations for Emcure Pharmaceuticals?
The overall consensus recommendation for Emcure Pharmaceuticals is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Emcure Pharmaceuticals dividend yield?
Emcure Pharmaceuticals does not currently pay a dividend.
Does Emcure Pharmaceuticals pay a dividend?
Emcure Pharmaceuticals does not currently pay a dividend.
When does Emcure Pharmaceuticals next pay dividends?
Emcure Pharmaceuticals does not currently pay a dividend.
How do I buy Emcure Pharmaceuticals shares?
To buy shares in Emcure Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Emcure Pharmaceuticals?
As of the previous close price of IN₹1,076.00, shares in Emcure Pharmaceuticals had a market capitalisation of IN₹203.88bn.
Where are Emcure Pharmaceuticals shares listed?
Here are the trading details for Emcure Pharmaceuticals:
- Country of listing: India
- Exchange: NSI
- Ticker Symbol: EMCURE
What kind of share is Emcure Pharmaceuticals?
Based on an overall assessment of its quality, value and momentum Emcure Pharmaceuticals is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Emcure Pharmaceuticals share price forecast for 2025?
The analyst consensus target price for shares in Emcure Pharmaceuticals is IN₹1,535.00. That is 42.66% above the last closing price of IN₹1,076.00.
Analysts covering Emcure Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of IN₹36.74 for the next financial year.
Find out moreWhat is the trend in the Emcure Pharmaceuticals share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Emcure Pharmaceuticals. Over the past six months, its share price has underperformed the S&P BSE 100 Index by -22.23%.
As of the last closing price of IN₹1,076.00, shares in Emcure Pharmaceuticals were trading -14.64% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Emcure Pharmaceuticals PE Ratio?
The Emcure Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is 22.94. The shares last closed at IN₹1,076.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Emcure Pharmaceuticals?
We do not have data on Emcure Pharmaceuticals' directors